ArriVent BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVBP research report →
About the company
ArriVent BioPharma, Inc. , a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
- CEO
- Zhengbin Yao
- IPO
- 2024
- Employees
- 77
- HQ
- Newtown Square, PA, US
Price Chart
- Market Cap
- $1.61B
- P/E
- -10.76
- P/S
- 0.00
- P/B
- 4.82
- EV/EBITDA
- -10.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -48.98%
- ROIC
- -48.36%
- Revenue
- $0 · 0.00%
- Net Income
- $-166,308,000 · -106.62%
- EPS
- $-4.32 · -68.75%
- Op Income
- $-177,534,000
- FCF YoY
- -128.72%
- 52W High
- $35.83
- 52W Low
- $16.10
- 50D MA
- $30.33
- 200D MA
- $24.04
- Beta
- 1.30
- Avg Volume
- 548.02K
Get TickerSpark's AI analysis on AVBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Parsey Merdad | other | 13,562 |
| Jun 18, 26 | Peterson Kristine | other | 13,562 |
| Jun 18, 26 | Hohneker John | other | 13,562 |
| Jun 18, 26 | Nolet Chris | other | 13,562 |
| Feb 2, 26 | LaChapelle Robin | other | 130,000 |
| Feb 2, 26 | Lutzker Stuart | other | 150,000 |
| Feb 2, 26 | Kung Winston | other | 140,000 |
| Feb 2, 26 | Yao Zhengbin | other | 550,000 |
| Feb 2, 26 | Kastenmayer James Paul | other | 130,000 |
| Dec 10, 25 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | sell | 555,555 |
Our AVBP coverage
Recent articles, reports, and earnings notes.
No research on AVBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVBP report →Similar companies
Peers in the same neighborhood.